相关临床试验
2
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
已完成
1
50.0%
招募中
1
50.0%
暂无批准数据
- Joyce A. Cramer has been named the recipient of the Epilepsy Foundation of America's Lifetime Accelerator Award for her career-long impact on epilepsy therapy development. - Cramer pioneered the incorporation of patient-reported outcomes into clinical trials, co-creating the Quality of Life in Epilepsy Inventory (QOLIE) and the Seizure Severity Questionnaire (SSQ). - She played a major role in the VA cooperative studies in the 1980s that identified optimal therapy for people with epilepsy and later served as President and Chief Scientific Officer of the Epilepsy Therapy Project. - According to the CDC, nearly 3.4 million Americans live with active epilepsy, underscoring the significance of Cramer's contributions to advancing innovative treatments.
- Xenon Pharmaceuticals will present seven posters at AES 2025, including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures. - The presentations will feature ≥48-month interim analysis data characterizing patterns of seizure freedom epochs with extended use of azetukalner, which could inform future clinical practice. - Additional data will highlight the impact of depression on epilepsy patients and new pre-clinical findings from the company's early-stage NaV1.1 program in Dravet syndrome. - Xenon will also host a symposium with the Epilepsy Foundation of America exploring depression and anxiety in epilepsy, featuring leading epileptologists from major medical centers.
